Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. [electronic resource]
Producer: 20150709Description: 5686-96 p. digitalISSN:- 1557-3265
- Anaplastic Lymphoma Kinase
- Benzoquinones -- pharmacology
- Carbazoles -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- diagnostic imaging
- Cell Line, Tumor
- Crizotinib
- DNA Mutational Analysis
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- genetics
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Inhibitory Concentration 50
- Lactams, Macrocyclic -- pharmacology
- Lung Neoplasms -- diagnostic imaging
- Models, Molecular
- Mutation
- Piperidines -- pharmacology
- Protein Conformation
- Protein Kinase Inhibitors -- pharmacology
- Pyrazoles -- pharmacology
- Pyridines -- pharmacology
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Tomography, X-Ray Computed
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.